This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?
by Zacks Equity Research
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
Baxter International (BAX) Q2 Earnings: What's in Store?
by Zacks Equity Research
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.
What's in Store for athenahealth (ATHN) in Q2 Earnings?
by Zacks Equity Research
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?
by Zacks Equity Research
Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.
Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is on a healthy growth trajectory of late and has rallied 17.7% over the past three months.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Thermo Fisher at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.
Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.
Thermo Fisher on an Acquisition Spree, Competition Rife
by Zacks Equity Research
On May 29, we issued an updated research report on Waltham, MA-based Thermo Fisher Scientific, Inc. (TMO), a scientific instrument maker and a world leader in serving science.
Why Is Thermo Fisher (TMO) Up 3.7% Since the Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2017 earnings report which has just released.
Thermo Fisher (TMO) Up 4.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report first-quarter 2017 results before the opening bell on Apr 26.
Should Value Investors Consider Thermo Fisher (TMO) Stock?
by Zacks Equity Research
Let's see if Thermo Fisher Scientific, Inc. (TMO) stock is a good choice for value-oriented investors right now from multiple angles.
Trump, Biogen and Amgen Hammer Healthcare ETFs
by Sweta Killa
After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
by Zacks Equity Research
On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines